Strongbridge Biopharma (SBBP) PT Lowered to $12 at Cantor Fitzgerald

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. SBUX
10. AXP

Go back to Strongbridge Biopharma (SBBP) PT Lowered to $12 at Cantor Fitzgerald

Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2018 Financial Results

February 26, 2019 7:30 AM EST

~ RECORLEV (levoketoconazole) Phase 3 Clinical Program and Type C FDA Meeting in First Quarter Progressing as Planned ~

~ $145 Million Upfront Cash Payment and $36.7 Million Equity Investment from Novo Nordisk in Fourth Quarter 2018 Significantly Strengthened Companys Financial Position Including Full Repayment of Outstanding Debt ~

~ KEVEYIS® (dichlorphenamide) Full-Year 2018 Revenue of $16.8 Million, a 140 Percent Increase over 2017 Revenue of $7 Million Following Launch in April 2017 ~

~ Full-Year 2019 KEVEYIS® (dichlorphenamide) Revenue Guidance of $18 to $20 Million; Company Anticipates Positive... More